CA3136171A1 - Mek-inhibitor for the treatment of viral and bacterial infections - Google Patents
Mek-inhibitor for the treatment of viral and bacterial infections Download PDFInfo
- Publication number
- CA3136171A1 CA3136171A1 CA3136171A CA3136171A CA3136171A1 CA 3136171 A1 CA3136171 A1 CA 3136171A1 CA 3136171 A CA3136171 A CA 3136171A CA 3136171 A CA3136171 A CA 3136171A CA 3136171 A1 CA3136171 A1 CA 3136171A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutically acceptable
- virus
- acceptable salt
- infection
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LULU101183 | 2019-04-16 | ||
| LU101183A LU101183B1 (en) | 2019-04-16 | 2019-04-16 | Novel mek-inhibitor for the treatment of viral and bacterial infections |
| PCT/EP2020/060692 WO2020212478A1 (en) | 2019-04-16 | 2020-04-16 | Novel mek-inhibitor for the treatment of viral and bacterial infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3136171A1 true CA3136171A1 (en) | 2020-10-22 |
Family
ID=66554457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3136171A Pending CA3136171A1 (en) | 2019-04-16 | 2020-04-16 | Mek-inhibitor for the treatment of viral and bacterial infections |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12350244B2 (https=) |
| EP (1) | EP3955908B1 (https=) |
| JP (2) | JP2022529343A (https=) |
| KR (1) | KR20210153642A (https=) |
| CN (1) | CN114007598A (https=) |
| AU (1) | AU2020258002B2 (https=) |
| BR (1) | BR112021020605A2 (https=) |
| CA (1) | CA3136171A1 (https=) |
| EA (1) | EA202192454A1 (https=) |
| ES (1) | ES3012533T3 (https=) |
| LU (1) | LU101183B1 (https=) |
| MX (1) | MX2021012604A (https=) |
| WO (1) | WO2020212478A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3912623B1 (en) * | 2020-05-20 | 2024-07-31 | Atriva Therapeutics GmbH | Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm |
| EP4186500A1 (en) * | 2021-11-24 | 2023-05-31 | Atriva Therapeutics GmbH | Mek inhibitors for the prevention and treatment of long covid syndrome |
| WO2024042050A1 (en) * | 2022-08-22 | 2024-02-29 | Atriva Therapeutics Gmbh | Use of mek1/2 inhibitors to synergistically potentiate the antiviral effect of direct-acting anti-coronavirus drugs |
| CN119931962B (zh) * | 2025-04-07 | 2025-08-05 | 北京华诺泰生物医药科技有限公司 | 一种人偏肺病毒的培养方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000040237A1 (en) * | 1999-01-07 | 2000-07-13 | Warner-Lambert Company | Antiviral method using mek inhibitors |
| KR20020012315A (ko) * | 1999-07-16 | 2002-02-15 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법 |
| DE10017480A1 (de) | 2000-04-07 | 2001-10-11 | Transmit Technologietransfer | Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren |
| WO2014056894A1 (en) | 2012-10-08 | 2014-04-17 | Westfaelische Wilhelms-Universitaet Muenster | Mek inhibitors in the treatment of virus diseases |
| CN113398271A (zh) | 2014-05-16 | 2021-09-17 | 归属疗法有限公司 | 抗流感病毒和金黄色葡萄球菌合并感染的新型抗感染策略 |
| EP3973960B1 (en) * | 2017-10-17 | 2025-09-03 | Atriva Therapeutics GmbH | Novel mek-inhibitor for the treatment of viral and bacterial infections |
| KR20220074869A (ko) * | 2019-08-27 | 2022-06-03 | 아트리바 테라퓨틱스 게엠베하 | Mek 억제제와 캡-의존성 엔도뉴클레아제 억제제의 조합 |
| JP7802365B2 (ja) * | 2019-10-08 | 2026-01-20 | アトリバ セラピューティクス ゲーエムベーハー | ハンタウイルス感染症の処置のためのｍｅｋ阻害剤 |
| EP3912623B1 (en) * | 2020-05-20 | 2024-07-31 | Atriva Therapeutics GmbH | Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm |
-
2019
- 2019-04-16 LU LU101183A patent/LU101183B1/en active IP Right Grant
-
2020
- 2020-04-16 ES ES20724748T patent/ES3012533T3/es active Active
- 2020-04-16 WO PCT/EP2020/060692 patent/WO2020212478A1/en not_active Ceased
- 2020-04-16 AU AU2020258002A patent/AU2020258002B2/en active Active
- 2020-04-16 MX MX2021012604A patent/MX2021012604A/es unknown
- 2020-04-16 JP JP2021561625A patent/JP2022529343A/ja active Pending
- 2020-04-16 EA EA202192454A patent/EA202192454A1/ru unknown
- 2020-04-16 EP EP20724748.7A patent/EP3955908B1/en active Active
- 2020-04-16 CA CA3136171A patent/CA3136171A1/en active Pending
- 2020-04-16 BR BR112021020605A patent/BR112021020605A2/pt not_active Application Discontinuation
- 2020-04-16 US US17/604,355 patent/US12350244B2/en active Active
- 2020-04-16 CN CN202080044394.4A patent/CN114007598A/zh active Pending
- 2020-04-16 KR KR1020217036169A patent/KR20210153642A/ko active Pending
-
2025
- 2025-05-19 JP JP2025083321A patent/JP2025124703A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025124703A (ja) | 2025-08-26 |
| KR20210153642A (ko) | 2021-12-17 |
| EA202192454A1 (ru) | 2022-03-22 |
| JP2022529343A (ja) | 2022-06-21 |
| LU101183B1 (en) | 2020-10-16 |
| CN114007598A (zh) | 2022-02-01 |
| US20220193017A1 (en) | 2022-06-23 |
| AU2020258002B2 (en) | 2025-12-18 |
| AU2020258002A1 (en) | 2021-11-18 |
| ES3012533T3 (en) | 2025-04-09 |
| BR112021020605A2 (pt) | 2021-12-07 |
| EP3955908A1 (en) | 2022-02-23 |
| MX2021012604A (es) | 2021-11-12 |
| US12350244B2 (en) | 2025-07-08 |
| WO2020212478A1 (en) | 2020-10-22 |
| EP3955908C0 (en) | 2025-01-22 |
| EP3955908B1 (en) | 2025-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240245637A1 (en) | Mek-inhibitor for the treatment of viral and bacterial infections | |
| US11135263B2 (en) | Novel-anti-infective strategy against influenza virus and S. aureus coinfections | |
| US12350244B2 (en) | MEK-inhibitor for the treatment of viral and bacterial infections | |
| EA047137B1 (ru) | Новый ингибитор mek для лечения вирусных и бактериальных инфекций | |
| HK40029715B (en) | Novel mek-inhibitor for the treatment of viral and bacterial infections | |
| HK40029715A (en) | Novel mek-inhibitor for the treatment of viral and bacterial infections | |
| EA042391B1 (ru) | Новый ингибитор mek для лечения вирусных и бактериальных инфекций | |
| BR112020007442B1 (pt) | Uso de PD-0184264 ou um sal farmaceuticamente aceitável do mesmo e composições farmacêuticas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220818 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241009 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241010 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - SMALL Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250407 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250407 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250409 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250409 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250812 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250812 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE Effective date: 20251127 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT Effective date: 20260307 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260307 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - SMALL Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260407 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260407 |